Connect your AI

EXOZ EXOZ Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

Ginkgo BioworksDNA

——

NAG

Niagen Bioscience, Inc. Common StockNAGE

——

UpexiUPXI

——

West Pharmaceutical ServicesWST

——

XCF Global, Inc. Class A Common StockSAFX

——

Other financials

Income statement

Revenue$17.5K—

Operating income-$2.4M-22.4%

Net income-$2.4M-27.7%

EPS (diluted)-$0.28-27.3%

Balance sheet

Cash & equivalents$1.4M-83.0%

Total debt$1.2M-8.8%

Total equity$1.5M-82.8%

Total assets$4.0M-65.1%

Cash flow

Operating cash flow-$1.5M-34.5%

CapEx$57.6K+85.5%

Free cash flow-$1.6M-35.8%

Valuation

Market cap$76.8M-5.6%

Enterprise value$76.57M+1.0%

P/S1,096.1×—

Profitability

Operating margin-14,489.6%—

Net margin-2,909.1%—

FCF margin-10,117.8%—

Returns & leverage

Return on equity-185.8%—

Debt / equity0.8×+0.6×

Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is EXOZ's remainder of fiscal year 2024?: EXOZ (EXOZ) reported remainder of fiscal year 2024 of $269.75K in Q1 2026.
How has EXOZ's remainder of fiscal year 2024 changed year-over-year?: EXOZ's remainder of fiscal year 2024 increased by 2.7% year-over-year, from $262.55K to $269.75K.